Newswise — New York, NY – Sept. 09, 2020 – The ATS Research Program is pleased to announce the new ATS/CSL Behring Research Award in Acute Respiratory Distress Syndrome or ARDS. The award will provide $50,000 in funding for one year.

ARDS is a life-threatening illness in which the lungs are severely inflamed. Tissue damage throughout the lungs causes tiny blood vessels to leak fluid. The air sacs (alveoli) collapse as a result or fill with fluid, preventing the lungs from working well.

“ARDS continues to have an enormous public health impact, with a high mortality and sequelae in survivors including long-term physical, cognitive, and mental health impairments,” said Renee Stapleton, MD, PhD, ATSF.  Dr. Stapleton is chair of a body of experts called the Critical Care Assembly of the ATS. “Continued research on ARDS pathogenesis and novel therapies is paramount to help decrease the suffering from this devastating syndrome.  The partnership between the ATS and CSL Behring to offer this grant is an amazing opportunity for young critical care investigators that will undoubtedly have a significant impact on the field and on the lives of patients and their loved ones.”

“Innovation is a core value at CSL Behring,” said Lars Groenke, MD, R&D lead, Respiratory Therapeutic Area, CSL Behring. “Supporting ventures like the ATS Research Program are fundamental to advancing clinical research, innovating and ultimately, improving outcomes for patients with acute respiratory distress syndrome (ARDS). We are proud to partner with ATS on this timely research topic.”

The application process will open Oct. 1, 2020.

Interested applicants may hear more about this grant opportunity here.


About the ATS Research Program The American Thoracic Society and its Research Program are improving respiratory health worldwide by supporting young investigators in pulmonary, critical care, and sleep medicine. The ATS Research Program, established in 2004, bolsters new investigators as they strive to launch independent research careers dedicated to innovation in patient care.

Since 2004, the Research Program has awarded $19.3 million in research grants to 263 investigators who have gone on to secure more than $330 million in federal funding. That's a return on investment of $17 per dollar awarded.


About CSL Behring

CSL Behring is a global biotherapeutics leader driven by its promise to save lives. Focused on serving patients’ needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, respiratory disease, and neurological disorders. The company’s products are also used in cardiac surgery, burn treatment and to prevent hemolytic disease of the newborn.

CSL Behring operates one of the world’s largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX:CSL;USOTC:CSLLY), headquartered in Melbourne, Australia, employs more than 26,000 people, and delivers its life-saving therapies to people in more than 100 countries. For inspiring stories about the promise of biotechnology, visit Vita and follow us on


Register for reporter access to contact details